Patient-Reported Outcomes: Open-Label Trials Can Be Designed To Minimize Bias, US FDA Says
Executive Summary
With the expectation for increasing amounts of patient experience data comes the need for the FDA and sponsors to consider, and account for, the degree to which open-label bias influences oncology trial PROs; agency staff suggest trial design elements and analytic approaches for dealing with bias at a meeting on cancer clinical outcomes assessments.